IDT: Good Medicine

Scott Power

Morgans

IDT: Good Medicine. Under new management IDT is shifting its focus from contract manufacture of pharmaceuticals to more in house development. The acquisition of a portfolio of generic drugs from a global generics company will see IDT capture significantly higher margin than it currently does as a supplier of APIs. The next 18 months will see revenue grow and the business move to profitability. We initiate with an ADD recommendation and a DCF valuation and price target of A$0.37. Full report here: (VIEW LINK)


2 topics

Scott Power
Scott Power
Senior Analyst
Morgans

Senior Analyst at Morgans covering healthcare, life science, telecommunications, technology and media. I've spent the last twenty years investing in and researching emerging companies and have developed a wide network of contacts across these...

Expertise

No areas of expertise

I would like to

Only to be used for sending genuine email enquiries to the Contributor. Livewire Markets Pty Ltd reserves its right to take any legal or other appropriate action in relation to misuse of this service.

Personal Information Collection Statement
Your personal information will be passed to the Contributor and/or its authorised service provider to assist the Contributor to contact you about your investment enquiry. They are required not to use your information for any other purpose. Our privacy policy explains how we store personal information and how you may access, correct or complain about the handling of personal information.